Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb study of IZD334 in high cardiovascular risk patients with stable coronary artery disease and elevated CRP
NL-OMON49686Phase 2Withdrawn
- Sponsor
- Inflazome
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of selnoflast in coronary arteriosclerosis and atherosclerosis (4 arms), sponsored by Inflazome. Primary endpoints: Safety and tolerability of IZD334 and Percent change from baseline in plasma CRP with IZD334 450 mg versus placebo. Planned start Jun 2020; status: withdrawn.
02
Drugs
selnoflast
03
Conditions
coronary arteriosclerosisatherosclerosis
Beyond the preview
Go deeper on NL-OMON49686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49686.